Compare ASPN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPN | AVIR |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 413.1M |
| IPO Year | 2011 | 2020 |
| Metric | ASPN | AVIR |
|---|---|---|
| Price | $5.45 | $4.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $7.75 | ★ $9.42 |
| AVG Volume (30 Days) | ★ 882.8K | 270.2K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | $271,103,000.00 | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.30 | $2.87 |
| 52 Week High | $8.64 | $6.45 |
| Indicator | ASPN | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 25.13 |
| Support Level | $5.25 | $3.34 |
| Resistance Level | $5.60 | $4.46 |
| Average True Range (ATR) | 0.24 | 0.25 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 48.74 | 1.24 |
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology, supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Thermal Barrier segment and the United States market. Some of its products include Pyrogel XTE, Cryogel Z, Spaceloft Subsea, and others.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.